ALT vs RYTM
ALT: A clinical-stage biopharmaceutical company developing dual-agonist peptide therapeutics targeting the massive obesity and metabolic disease markets. RYTM: Rhythm Pharmaceuticals is a precision medicine company developing targeted MC4R agonist therapies for patients living with rare, severe obesity-related neuroendocrine diseases.
Side-by-side fundamentals
| Metric | ALT | RYTM | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.81 | $103.97 | |
| Market cap as of 2026-07-23 | $546M | $7.1B | |
| PEG as of 2026-07-23 | n/a | -2.97 | |
| Net margin as of 2026-07-23 | -214861.0% | -93.3% | RYTM higher |
| Gross margin as of 2026-07-23 | +100.5% | +89.4% | ALT higher |
| Operating margin as of 2026-07-23 | -230461.0% | -90.9% | RYTM higher |
| ROE as of 2026-07-23 | -42.6% | -86.5% | ALT higher |
| ROA as of 2026-07-23 | -35.6% | -45.0% | ALT higher |
| Debt / equity as of 2026-07-23 | 0.12 | 0.46 | ALT lower |
| Revenue growth (YoY) as of 2026-07-23 | +80.0% | +58.7% | ALT higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +100.2% | |
| Beta as of 2026-07-23 | 0.14 | 1.97 | |
| 1-year return as of 2026-07-22 close | -30.4% | +18.4% | RYTM higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.